BCD-261
/ Biocad
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
January 14, 2026
Another drug for Crohn’s disease treatment is being developed in Russia
(GxP News)
- "'A molecule discovered earlier and enzymes synthesized based on it through biotechnological means have shown potential effectiveness in several areas.'...According to Tekutyeva, preclinical trials of the enzyme-based drug are now underway...According to the company’s website, patients are currently being recruited for Phase II...Eligible patients are those 18-75 for whom prior therapies—glucocorticoids, immunosuppressants, or biologics—have proven ineffective. The study will take place in 33 hospitals across 17 Russian cities."
Preclinical • Trial status • Crohn's disease
July 25, 2025
ULTRAMARINE: A Randomized Double-Blind, Placebo-Controlled Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Ulcerative Colitis
(clinicaltrials.gov)
- P2 | N=198 | Recruiting | Sponsor: Biocad
New P2 trial • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
July 25, 2025
COMANDOR: Clinical Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of BCD-261 in Subjects With Moderate to Severe Active Crohn's Disease
(clinicaltrials.gov)
- P2 | N=204 | Recruiting | Sponsor: Biocad
New P2 trial • Crohn's disease • Gastroenterology • Immunology • Inflammatory Bowel Disease
1 to 3
Of
3
Go to page
1